Pregled bibliografske jedinice broj: 460974
The clinical application of pharmacogenetics : antidepressant drugs
The clinical application of pharmacogenetics : antidepressant drugs // IV. Makedonski psihijatrijski kongres so međunarodno učestvo : Knjiga na apstrakti ; u: Makedonski medicinski pregled / Novotni, Antoni (ur.).
Skopje: Makedonsko lekarsko društvo, Združenie na psihijatri na Republika Makedonija, 2009. str. 21-21 (predavanje, nije recenziran, sažetak, znanstveni)
CROSBI ID: 460974 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The clinical application of pharmacogenetics : antidepressant drugs
Autori
Mihaljević-Peleš, Alma ; Šagud, Marina ; Božina, Nada
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
IV. Makedonski psihijatrijski kongres so međunarodno učestvo : Knjiga na apstrakti ; u: Makedonski medicinski pregled
/ Novotni, Antoni - Skopje : Makedonsko lekarsko društvo, Združenie na psihijatri na Republika Makedonija, 2009, 21-21
Skup
Makedonski psihijatrijski kongres so međunarodno učestvo (4 ; 2009)
Mjesto i datum
Ohrid, Sjeverna Makedonija, 27.05.2009. - 31.05.2009
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
pharmacogenetics; antidepressant drugs
Sažetak
There is substantial unexplained interindividual variability in treatment with antidepressants, as a proportion of patients given a regular dose do not respond properly or experience limiting side affects. Because of that the concept of individualized drug therapy on the basis of pharmacogenetics has become a major issue in psychopharmacology. The nature of drug response is highly complex involving genetic and environmental factors like age, gender, hepatic and renal status, nutrition, smoking and alcohol intake. Despite much effort, prediction of response is still hampered by many methodological problems and is not yet available for the clinical practice. However, a few of the results are now ready for translation into clinical practice. For exemplar, cytochrome P450 genotyping would be big step forward. Individualized drug treatment by genotyping cytochrome P450 could improve treatment, reduce side effects and increase drug compliance. The clinical application of pharmacogenetics requires integration of pharmacogenetic testing and interpretation. This review focuses primarily on recent knowledge and findings about cytochrome P450, p-glycoprotein (MDR1), serotonin transporter (SERT) and polymorphisms in neurotransmitter systems in the treatment with antidepressants. These findings are already relevant for clinicians or might become important in the near future.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1083509-3513 - Farmakogenetska varijabilnost u psihijatrijskih bolesnika (Mihaljević-Peleš, Alma, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb